High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
- PMID: 23727085
- DOI: 10.1016/j.jacc.2013.05.016
High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Abstract
The role of inflammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well established. Of the wide array of inflammatory biomarkers that have been studied, high-sensitivity C-reactive protein (hsCRP) has received the most attention for its use in screening and risk reclassification and as a predictor of clinical response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and plaque deposition and is associated with increased CV disease (CVD) risk, definitive randomized evidence for its role as a causative factor in atherothrombosis is lacking. Whether measurement of hsCRP levels provides consistent, clinically meaningful incremental predictive value in risk prediction and reclassification beyond conventional factors remains debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews 4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice: 1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the quality of hsCRP as a biomarker of risk; and 4) the use of hsCRP as a tool to initiate or tailor statin therapy. Furthermore, we highlight recommendations from societies and important considerations when using hsCRP to guide treatment decisions in the primary prevention setting.
Keywords: CAC; CHD; CRP; CVD; FRS; Framingham risk score; LDL-C; MI; NRI; RRS; Reynolds risk score; atherosclerosis; cardiovascular disease; coronary artery calcium; coronary heart disease; high-sensitivity C-reactive protein; hsCRP; inflammation; low-density lipoprotein cholesterol; myocardial infarction; net reclassification improvement; prevention; statins.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Inflammation, C-reactive protein, and atherothrombosis.J Periodontol. 2008 Aug;79(8 Suppl):1544-51. doi: 10.1902/jop.2008.080249. J Periodontol. 2008. PMID: 18673009 Review.
-
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.
-
High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.Int J Cardiol. 2013 Oct 15;168(6):5126-34. doi: 10.1016/j.ijcard.2013.07.113. Epub 2013 Aug 24. Int J Cardiol. 2013. PMID: 23978367 Review.
-
C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.J Am Coll Cardiol. 2007 May 29;49(21):2129-38. doi: 10.1016/j.jacc.2007.02.052. Epub 2007 Apr 30. J Am Coll Cardiol. 2007. PMID: 17531663 Review.
-
Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.Am J Cardiovasc Drugs. 2010;10(6):383-400. doi: 10.2165/11204600-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 21090831 Review.
Cited by
-
C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review).Exp Ther Med. 2020 Aug;20(2):1211-1219. doi: 10.3892/etm.2020.8840. Epub 2020 Jun 4. Exp Ther Med. 2020. PMID: 32765664 Free PMC article. Review.
-
A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis.J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3500-3506. doi: 10.1016/j.jaip.2020.07.018. Epub 2020 Jul 25. J Allergy Clin Immunol Pract. 2020. PMID: 32721606 Free PMC article.
-
Inflammation and Its Determinants in Patients With Chronic Kidney Disease: A Study From North Eastern Region of India.Cureus. 2022 Jan 4;14(1):e20917. doi: 10.7759/cureus.20917. eCollection 2022 Jan. Cureus. 2022. PMID: 35145813 Free PMC article.
-
Impact of Treatment Modality on Vascular Function in Coarctation of the Aorta: The LOVE - COARCT Study.J Am Heart Assoc. 2019 Apr 2;8(7):e011536. doi: 10.1161/JAHA.118.011536. J Am Heart Assoc. 2019. PMID: 30929556 Free PMC article.
-
High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study.BMC Cardiovasc Disord. 2022 May 25;22(1):241. doi: 10.1186/s12872-022-02663-0. BMC Cardiovasc Disord. 2022. PMID: 35614388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous